Clarity Pharmaceuticals Ltd (ASX:CU6 – Get Free Report) insider Colin Biggin purchased 542,835 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was bought at an average cost of A$0.67 ($0.43) per share, for a total transaction of A$363,156.62 ($235,815.98).
Clarity Pharmaceuticals Price Performance
About Clarity Pharmaceuticals
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2.
Featured Stories
- Five stocks we like better than Clarity Pharmaceuticals
- Earnings Per Share Calculator: How to Calculate EPS
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Airline Stocks – Top Airline Stocks to Buy Now
- MarketBeat Week in Review – 8/5 – 8/9
- What is a buyback in stocks? A comprehensive guide for investors
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Clarity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
